Could a vaccine stop lung cancer before it starts?

NCT ID NCT07169617

Not yet recruiting Prevention Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a vaccine called SurVaxM in 80 current or former heavy smokers at high risk for lung cancer. The vaccine trains the immune system to recognize and attack cells that produce a protein called survivin, which is common in cancer cells. The goal is to see if the vaccine can trigger antibodies that may prevent lung cancer from developing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SurVaxM (survivin peptide vaccine) with montanide and sargramostim
What this could lead to: If it works, this could point toward a vaccine that prevents lung cancer in people at high risk, like heavy smokers.
What could go wrong: This is an early phase II trial with only 80 participants, so results may not apply broadly. The vaccine may not trigger a strong enough immune response or prevent cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung carcinoma lung neoplasm lung cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CARCINOMA

Contacts and locations

Locations

Northwestern University

Chicago, Illinois, 60611, United States
Rocky Mountain Regional VA Medical Center

Aurora, Colorado, 80045, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
University of Tennessee - Knoxville

Knoxville, Tennessee, 37920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.